Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Artelo Biosciences filed a provisional patent application for ART27.13 to cover use in obesity as monotherapy and in combination with GLP-1 receptor agonists after a diet-induced obesity (DIO-2) mouse study reported roughly 20% weight loss with ART27.13 alone and ~40% in combination with semaglutide, plus changes in glucose tolerance and bone mineral density.